Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

The agreement is seen as a win for global health ahead of the US withdrawal from the WHO and amidst foreign aid cuts by the ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...

Leveraging Trump’s impending tariffs, pharma companies have called on Europe again to change regulation, threatening a US ...

The clinical trial (NCT04079166) is part of the NHS Cancer Vaccine Launch Pad (CVLP), a framework launched in May 2024 to ...

The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.